http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0858802-A3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2836f8341ba126b9578fbe852b71fab5 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
filingDate | 1997-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05a859d81304bfce89a10af2fd181c75 |
publicationDate | 2000-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-0858802-A3 |
titleOfInvention | Pharmaceutical preparation of thioctic acid for oral administration |
abstract | (a) der Wirkstoffgehalt 70 bis 95 Gew.-%, bezogen auf dasnGesamtgewicht der Darreichungsform, beträgt, (b) mindestens 90 Gew.-% des Wirkstoffs eine Partikelgrößenkleiner als 200 µm aufweisen und (c) die Darreichungsform poröses amorphes Siliciumdioxidnin einer Menge von 0,2 bis 5 Gew.-%, bezogen auf dasnGesamtgewicht der Darreichungsform, und zum Rest pharmazeutischnannehmbare Hilfsstoffe enthält. A tablet-like dosage form for the active ingredient thioctic acid is described, which is characterized in that (a) the active ingredient content is 70 to 95% by weight, based on the total weight of the dosage form, (b) at least 90% by weight of the active ingredient have a particle size of less than 200 μm and (c) the dosage form contains porous amorphous silicon dioxide in an amount of 0.2 to 5% by weight, based on the total weight of the dosage form, and the remainder pharmaceutically acceptable excipients. |
priorityDate | 1997-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.